Ascend Laboratories, LLC Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg recall: Failed Dissolution Specifications: Olmesartan Medoxomil content below
Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications
The hazard: Potency, impurity or stability failure
The recall concerns the strength or purity of the medicine rather than contamination of it, which changes what you should do about a dose you have already taken.
What the notice says: Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications
Why it matters: The product failed a specification test: it may contain more or less active ingredient than the label states, carry an impurity, or degrade before its expiry date. A sub-potent dose can leave a condition untreated; a super-potent one can cause an overdose.
Symptoms and when to call a doctor
The risk depends entirely on the drug. For a medicine where dose matters closely — a blood thinner, an anti-epileptic, a thyroid or heart medicine, insulin — talk to your prescriber before changing anything. Seek urgent care if you have symptoms that suggest too much drug, or if the condition the medicine controls starts breaking through.
This page is general information, not medical advice. If you feel unwell, a clinician who can see you is the only person able to judge your case.
Recall details
- Recall number
- D-0556-2026
- Published
- June 10, 2026
- Risk level
- Class II
- Status
- Ongoing
- Issued by
- U.S. Food and Drug Administration
- Brand
- Ascend Laboratories, LLC
- Product type
- Prescription & OTC drugs
- Units affected
- 15,696 x 30's bottles
- Distribution
- Nationwide
- Made in
- United States
- Lot / code info
- Lot: 24123460, Expires: October 31, 2027.
Products covered by this recall
Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg, Rx Only, 30-count bottle, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC., Parsippany, NJ 07054, NDC 67877-501-30.
Check your product
The notice names 8 codes you can read straight off the package. Type the one printed on yours and the list below narrows to it.
Lot or batch code
Usually ink-stamped near the seam, the cap or the bottom of the pack.
- 24123460
Best-by / use-by date
Printed beside the lot code, not on the price sticker.
- October 31
- 2027. — 15
- 696 x 30
NDC number
On the carton and again on the bottle or blister label.
- 67877-501-30
Package size
Match the net weight or the piece count on the front of the pack.
- 5 mg
- 40 mg
- 30 count
Codes are lifted verbatim from the FDA — Drug enforcement notice. A code that is missing here may still be covered — the official notice is the complete list.
What to do about Potency
Ascend Laboratories, LLC — The recall concerns the strength or purity of the medicine rather than contamination of it, which changes what you should do about a dose you have already taken.
- Check the lot number on your pack against the codes listed above before you do anything else.
- Report any change in how the medicine is working to FDA MedWatch, which is where most of these signals originate.
- Do not stop a prescription on your own. For most conditions an uncertain dose is safer than no dose while you get advice.
- Call your prescriber or pharmacist and ask whether to swap the lot, re-test, or change nothing.
Getting a replacement supply
Do not let a refund question interrupt your treatment. Deal with the supply first and the money second.
- Call the pharmacy before you run low. They can see which lot they dispensed to you and will usually swap it the same day.
- Insurers do not normally count a recall replacement against a refill limit. If one is refused, ask the pharmacist to call it through as a recall override.
- Over-the-counter products are refunded at the till like any other purchase; the recall notice on your phone is enough to explain the return.
- If the manufacturer runs a direct reimbursement form, it will be linked from the official notice on this page.
Company contact: Ascend Laboratories, LLC — 135 Us Highway 202 206 Ste 15, Bedminster, NJ, 07921-2608
The official notice
This page summarises a notice published by U.S. Food and Drug Administration. The agency notice is the authoritative version — read it before you act, and treat it as the final word if anything here looks different.
Open the FDA — Drug enforcement record U.S. Food and Drug Administration recalls
Questions people ask about this recall
Why was Ascend Laboratories, LLC prescription & otc drugs recalled?
Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications
How do I know if I have the recalled product?
Match the codes printed on your package against the notice: lot code 24123460; best-by date October 31 or 2027. — 15. If the code on your package is not on that list, your unit is outside the recall.
What should I do with it right now?
Check the lot number on your pack against the codes listed above before you do anything else.
Can I get my money back?
Call the pharmacy before you run low. They can see which lot they dispensed to you and will usually swap it the same day.
Where was the recalled product sold?
It was distributed nationwide.
Related recalls
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 75 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran Etexilate Capsules, 150 mg recall: Failed impurity/degradation specification: an OOS result observed in Related
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 150 mg, 20-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…
-
Class II · 3 months ago
Ascend Laboratories, LLC Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg recall: Failed Dissolution Specifications; Olmesartan Medoxomil content below
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
-
Class III · 3 months ago
Ascend Laboratories, LLC Dabigatran etexilate Capsules, 110 mg, 60-count carton recall: Failed Impurities/Degradation Specifications: OOS result was observed during
Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…